Carol Salisbury
Family · Lansing, MINPI 1831208776
Payments from drug & device makers
Across 317 payments — averaging $24.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3K
- Viiv Healthcare Company$2K
- AbbVie$867
- Merck$363
- Otsuka America Pharmaceutical, Inc.$255
- Axsome Therapeutics, Inc.$171
- plus $931 from 14 others
What the payments were for
- Consulting fees$74010%
- Food & beverage$6,82189%
- Education$1282%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 75 | $3,436 |
| Viiv Healthcare Company | 117 | $1,666 |
| AbbVie | 50 | $867 |
| Merck | 12 | $363 |
| Otsuka America Pharmaceutical, Inc. | 17 | $255 |
| Axsome Therapeutics, Inc. | 3 | $171 |
| Novo Nordisk | 8 | $168 |
| Johnson & Johnson(2 entities) | 8 | $145 |
| Janssen Products, LP | 1 | $100 |
| Lilly USA, LLC | 6 | $98 |
| Theratechnologies Inc. | 1 | $90 |
| GSK | 4 | $71 |
| Vanda Pharmaceuticals Inc. | 3 | $66 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $59 |
| Pfizer | 3 | $42 |
| Janssen Scientific Affairs, LLC | 2 | $30 |
| Abbott | 1 | $16 |
| Dynavax Technologies Corporation | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,690 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 148 | $565,265 |
| EpclusaSofosbuvir/Velpatasvir | 20 | $481,632 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 57 | $268,398 |
| DovatoDolutegravir Sodium/Lamivudine | 88 | $254,671 |
| DescovyEmtricitabine/Tenofov Alafenam | 77 | $166,587 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 31 | $106,447 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 25 | $103,644 |
| TivicayDolutegravir Sodium | 36 | $78,238 |
| JardianceEmpagliflozin | 48 | $44,031 |
| JulucaDolutegravir/Rilpivirine | 11 | $34,430 |
| Isentress HdRaltegravir Potassium | 13 | $24,828 |
| IsentressRaltegravir Potassium | 12 | $22,378 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $21,212 |
| PifeltroDoravirine | 12 | $19,190 |
| FarxigaDapagliflozin Propanediol | 20 | $18,153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Epclusa, Descovy, Genvoya | $3,436 | $1,317,129270 claims |
| Viiv Healthcare CompanyDovato, Triumeq, Tivicay, Juluca | $1,666 | $473,785166 claims |
| Janssen Products, LPSymtuza | $100 | $268,39857 claims |
| MerckIsentress Hd, Isentress, Pifeltro | $363 | $66,39737 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $71 | $39,30379 claims |
| Novo NordiskOzempic | $168 | $17,82219 claims |
| Lilly USA, LLCTrulicity | $98 | $12,64614 claims |
| PfizerEliquis | $42 | $6,20911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.
Other family in Lansing
- Iris ZinkLansing$37K
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.